There is no doubt that among hundreds of IVD companies, Jiu'an Medical will become the biggest winner in the US market, and this company's "magic story" continues.
On June 22, Jiu'an Medical once again showed its true nature as a "demon stock" and closed the daily limit at 65.42 yuan per share.
According to the 2021 annual report, Jiu'an Medical has newly invested in the establishment of Zaozhuang Jiupeng Automobile Sales and Service Co., Ltd., whose main business is the sales of new energy vehicles and complete vehicles.
A listed company that makes COVID-19 home self-test products is actually involved in the concept of new energy? Naturally, the regulator immediately issued a letter of inquiry, asking it to explain Zaozhuang Jiupeng's business model and profit model in the sales of new energy vehicles and complete vehicles, and whether there were "concepts" and "hot spots" to speculate on the stock price.
On June 21, Jiu'an Medical responded to the inquiry letter stating that Zaozhuang Jiupeng Automobile Sales and Service Co., Ltd., which provides sales services for Xiaopeng Motors, has been established for a relatively short time and currently has only one store. The company's new energy The automobile sales business has a small impact on the company's overall performance.
In general, Jiuan Medical stated that the company has never carried out large-scale publicity for the establishment of a new energy vehicle sales company, so there is no such thing as "concept" or "hot spot".
Jiu'an Medical, which started out selling blood pressure monitors, has been producing COVID-19 test kits since last year and has been on the market in the United States and is selling like hotcakes. At the beginning of this year, Jiu'an Medical Connection announced and the U.S. Army Contract Management Command (ACC)'s order contracts, totaling US$1.775 billion, were awarded.
On the evening of April 29, the company disclosed its 2021 results and first quarter results for 2022. Net profit in 2021 is 909 million yuan, a year-on-year increase of 274.96%; in the first quarter of this year, revenue was 21.737 billion yuan, and net profit was 14.312 billion yuan, a year-on-year increase of 37527.35%. This profit growth rate is unparalleled among more than 4,000 A-share listed companies. dust.
In other words, in the first three months of this year, Jiu'an Medical made an average daily net profit of 159 million yuan. We must know that from its listing in 2007 to 2020, Jiu'an Medical's total profit was less than 200 million yuan. Flush iFinD data shows: The total revenue of all A-share medical device-related companies in the first quarter of this year was 101.3 billion yuan, and Jiu'an alone accounted for one-fifth of the sector's total revenue.
At the performance briefing on April 29, the company attributed the performance growth to "a significant increase in sales of iHealth kit products due to the development of the epidemic in the United States."
iHealth It is a subsidiary of Jiu'an Medical in the United States. The iHealth kit is sold to both C-side and B-side in the United States. Since its launch in the United States, it has received a lot of orders. The annual report shows that 77.59% of the company's revenue in 2021 comes from the iHealth series of products; for the continued substantial growth in performance in the first quarter of this year, Jiu'an Medical said that affected by the development of the epidemic in the United States, local demand for new crown antigen detection kit products has increased significantly.
Regarding the fact that the outside world has always labeled Jiu'an Medical as a "demon stock", the company's founder and chairman Liu Yi once said in an interview with "Chinese Entrepreneur", "Although the concept of COVID-19 testing is popular, it is not a castle in the air. At present, it is not a castle in the air. So far, if we don’t lose performance, can we be a monster stock? ”